Variable | Baseline when switching to taking TAF from TDF |
---|---|
Number of patients | 70 |
Median age, year (interquartile range) | 44 (37–49) |
Male, n (%) | 65 (92.9) |
Median HIV-1 RNA, copies/mL (interquartile range) | < 40 (< 40 to < 40) |
Median CD4 counts, cells/μL (interquartile range) | 480 (332–627) |
Third agent class drugs | |
INSTI, n (%) | 61 (87.1) |
Dolutegravir (DTG), n (%) | 32 (45.7) |
Elvitegravir (EVG), n (%) | 18 (25.7) |
Raltegravir (RAL), n (%) | 11 (15.7) |
PI, n (%) | 9 (12.9) |
Boosted darunavir (bDRV), n (%) | 9 (12.9) |
Median TDF duration, weeks (interquartile range) | 274 (128–454) |
Median serum creatinine, mg/dL (interquartile range) | 0.84 (0.72–0.97) |
Median eGFR, mL/min/1.73 m2 (interquartile range) | 80.89 (68.12–92.02) |
GFR categories, (mL/min/1.73 m2)a | |
G1 (≧ 90), % | 27.1 |
G2 (60–89), % | 58.6 |
G3a (45–59), % | 12.9 |
G3b (30–44), % | 1.4 |
Median Uβ2MG, μg/L (interquartile range) | 267 (114–869) |
UP 1+ or 2+, % | 6.0 |
Median BUN, mg/dL (interquartile range) | 13.5 (11.0–16.0) |
Median body weight, kg (interquartile range) | 70.1 (60.8–75.9) |
Median BMI, kg/m2 (interquartile range) | 23.4 (21.3–26.1) |
Median TG, mg/dL (interquartile range) | 145 (91–230) |
Hypertension, n (%) | 10 (14.3) |
Diabetes mellitus, n (%) | 3 (4.3) |
Abnormal lipid metabolism, n (%) | 9 (12.9) |
Fibrate treatment, n (%) | 5 (7.1)b |
Statin treatment, n (%) | 4 (5.7)b |